alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 126–150 of 315 studies with an author at University of California, Los Angeles (US) (page 6 of 13) · 28,580 in the whole library · How the 0–100 score works

Download bibliography of these 315 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 14,058 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Movement disorders : official journal of the Movement Disorder Society 2015-08-21

Loss-of-function mutations in the GBA gene are associated with more severe cognitive impairment in PD, but the nature of these deficits is not well understood and whether common GBA polymorphisms influence cognitive performance in PD is not yet known. 4 key findings →

Participants: 60 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neighborhood disadvantage and dementia incidence in a cohort of Asian American and non‐Latino White older adults in Northern California

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Alzheimer s & Dementia 2022-04-06

Among non-Latino Whites, ADI was associated with dementia incidence (most vs. least disadvantaged ADI quintile HR = 1.09, 95% confidence interval [CI] = 1.02-1.15). 4 key findings →

Participants: 18,103 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

APOE-ε4 carriership and dementia risk over 10 years among Asian American and White older adults

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Alzheimer's & Dementia 2026-07

Despite differences in prevalence of APOE-ε4, its association with dementia risk was similar across Chinese, Japanese, Filipino, and non-Latino White participants. 2 key findings →

Design: cohort Participants: 46,325 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model

✓ Peer-reviewed alzhub usefulness score 55 out of 100. The Journal of neuroscience : the official journal of the Society for Neuroscience 2005-03-01

Epidemiological studies suggest that increased intake of the omega-3 (n-3) polyunsaturated fatty acid (PUFA) docosahexaenoic acid (DHA) is associated with reduced risk of Alzheimer's disease (AD). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study

✓ Peer-reviewed alzhub usefulness score 55 out of 100. JAMA neurology 2014-01-01

Infant ε4 carriers had lower MWF and GMV measurements than noncarriers in precuneus, posterior/middle cingulate, lateral temporal, and medial occipitotemporal regions, areas preferentially affected by AD, and greater MWF and GMV measurements in extensive frontal regions and measurements were also significant in the subset of 2- to 6-month-old infants (MWF differences, P Conclusions and relevance While our findings should be considered preliminary, this study demonstrates some of the earliest brain changes associated with the genetic predisposition to AD. 1 key finding →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Movement disorders : official journal of the Movement Disorder Society 2007-12-01

A preceding article described the clinical features of Parkinson's disease dementia (PD-D) and proposed clinical diagnostic criteria for "probable" and "possible" PD-D. The main focus of this article is to operationalize the diagnosis of PD-D and to propose practical guidelines based on a two level process depending upon the clinical scenario and the expertise of the evaluator involved in the assessment. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neurons selectively targeted in frontotemporal dementia reveal early stage TDP-43 pathobiology

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Acta neuropathologica 2018-12-03

TAR DNA-binding protein 43 (TDP-43) aggregation is the most common pathological hallmark in frontotemporal dementia (FTD) and characterizes nearly all patients with motor neuron disease (MND). 3 key findings →

Participants: 17 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The effect of alcohol and tobacco consumption, and apolipoprotein E genotype, on the age of onset in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 55 out of 100. International journal of geriatric psychiatry 2010-05-01

The results suggest that APOE epsilon4 and heavy drinking and heavy smoking lower the age of onset for AD in an additive fashion. 2 key findings →

Design: cross-sectional Participants: 397 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Patient and Caregiver Outcomes of Health System, Community-Based, and Usual Dementia Care

✓ Peer-reviewed alzhub usefulness score 55 out of 100. JAMA Internal Medicine 2025-09-02

A total of 2176 person living with dementia-caregiver dyads were enrolled; 1271 persons living with dementia (58.4%) and 1650 caregivers (75.8%) were female, and their mean (SD) age were 80.6 (8.5) years and 65.2 (12.3) years, respectively. 5 key findings →

Participants: 1,271 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Voiceprints of cognitive impairment: analyzing digital voice for early detection of Alzheimer’s and related dementias

✓ Peer-reviewed alzhub usefulness score 55 out of 100. npj Dementia 2025-11-03

Early detection of Alzheimer's disease (AD) is critical yet challenging, particularly in younger individuals. 1 key finding →

Design: longitudinal study Participants: 120 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Clinical and neuropathological associations of plasma Aβ42/Aβ40, p‐tau217 and neurofilament light in sporadic frontotemporal dementia spectrum disorders

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring 2025-01-01

Plasma p‐tau217 has clinical, neuroimaging, and neuropathological correlates in sporadic FTD and may identify FTD cases with AD co‐pathology. 1 key finding →

Design: longitudinal study Participants: 620 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Intraoperative hypotension and postoperative delirium among older high-risk patients undergoing major noncardiac surgery: a retrospective single-centre cohort study

✓ Peer-reviewed alzhub usefulness score 55 out of 100. BJA Open 2025-10-15

Although intraoperative hypotension initially appeared to be associated with postoperative delirium, this association was no longer significant when accounting for temporal improvements in perioperative care. 5 key findings →

Design: cohort study Participants: 5,171 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

End-of-Life Care and Health Care Spending for Medicare Beneficiaries With Dementia in Accountable Care Organizations

✓ Peer-reviewed alzhub usefulness score 54 out of 100. JAMA Health Forum 2025-05-02

Of 162 034 eligible Medicare beneficiaries (mean [SD] age, 85.0 [7.9] years; 94 304 female [58.2%]), 51 191 (31.6%) were attributed to MSSP ACO. 2 key findings →

Design: cohort Participants: 162,034 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed